Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

May 31, 2024
RNS Number : 6665Q Stifel Nicolaus Europe Limited 31 May 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Total Voting Rights

May 30, 2024
RNS Number : 5265Q Renalytix PLC 30 May 2024   Renalytix plc ("Renalytix" or the "Company")   Total Voting Rights   LONDON and SALT LAKE CITY -   30 May 2024   -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX)   announces that at today's date, the Company's total issued share capital is   154,368,191

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

May 28, 2024
RNS Number : 0870Q Stifel Nicolaus Europe Limited 28 May 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Management Change

May 28, 2024
RNS Number : 9642P Renalytix PLC 28 May 2024   Renalytix plc ("Renalytix" or the "Company")   Management Change   LONDON and SALT LAKE CITY -   28 May 2024   -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX)   announces that O. James Sterling will step down from his role as Chief Financial Officer of

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

May 22, 2024
RNS Number : 4592P Stifel Nicolaus Europe Limited 22 May 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Block Admission & “At The Market” Sales Agreement

May 21, 2024
RNS Number : 1850P Renalytix PLC 21 May 2024   Renalytix plc ("Renalytix" or the "Company")   Block Admission and "At The Market" Sales Agreement LONDON and SALT LAKE CITY -   21 May 2024   -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX)   entered into an at-the-market offering agreement with H.C.

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

May 20, 2024
RNS Number : 0777P Stifel Nicolaus Europe Limited 20 May 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Form 8.3 - Renalytix plc

May 17, 2024
RNS Number : 9654O Renalytix PLC 17 May 2024   FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: DB Capital

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

May 17, 2024
RNS Number : 9105O Stifel Nicolaus Europe Limited 17 May 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Stifel Nicolaus Euro - Form 8.5 (EPT/NON-RI) - RENALYTIX

May 16, 2024
RNS Number : 7255O Stifel Nicolaus Europe Limited 16 May 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of
Displaying 51 - 60 of 582